Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 16/20 | 0.79 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.41 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.39 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12762825 | 0.94 | TLR4 (0.71) | TLR4LY96NR5A2NR5A1 | |
| SCHEMBL13296560 | 0.94 | TLR4 (0.71) | TLR4LY96NR5A2NR5A1 | |
| SCHEMBL6152143 | 0.94 | TLR4 (0.80) | TLR4LY96 | |
| SCHEMBL12560458 | 0.92 | TLR4 (0.67) | TLR4LY96NR5A2NR5A1 | |
| SCHEMBL13488524 | 0.92 | TLR4 (0.87) | TLR4LY96 | |
| Eritoran SCHEMBL10042160 | 0.89 | TLR4 (1.00) | TLR4LY96 | |
| Eritoran SCHEMBL12371609 | 0.89 | TLR4 (1.00) | TLR4LY96 | |
| Eritoran SCHEMBL14081112 | 0.89 | TLR4 (1.00) | TLR4LY96 | |
| Eritoran SCHEMBL21378839 | 0.89 | TLR4 (1.00) | TLR4LY96 | |
| Eritoran SCHEMBL10042165 | 0.89 | TLR4 (1.00) | TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-8481073-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-07-09 | — | — | US | disclosed |
| US-20130012683-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20120039980-A1 | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2012-02-16 | — | — | US | disclosed |
| US-7994154-B2 | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | Ersai R&D Management Co., Ltd. (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100268288-A1 | ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2010-10-21 | — | — | US | disclosed |
| US-20100227835-A1 | SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20060282123-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2006-12-14 | — | — | US | disclosed |
| US-20050186244-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-25 | — | — | US | disclosed |
| US-20050181009-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-18 | — | — | US | disclosed |
| US-20050175703-A1 | Polymer compositions and methods for their use | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-11 | — | — | US | disclosed |
| US-20050175665-A1 | In combination with antiscarring, antifibrotic, and antiinflammatory agents for preventing surgical adhesions, and cartilage loss; hypertrophic scars, keloids, arthritis, vascular disease; injection or topical administration | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-11 | — | — | US | disclosed |
| US-20050175664-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-11 | — | — | US | disclosed |
| US-20050169961-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-04 | — | — | US | disclosed |
| US-20050169960-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-08-04 | — | — | US | disclosed |
| US-20050158356-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-21 | — | — | US | disclosed |
| US-20050152946-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-20050154374-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-20050152941-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039980-A1 | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ILK, FN1, COL1A1 | TLR4 948/4885LY96 57/4885NR5A2 4705/4885 |
| US-20050152946-A1 | Implantable sensors and implantable pumps and anti-scarring agents | MMP1, CDKN1A, MKI67 | TLR4 2345/4885LY96 617/4885NR5A2 2005/4885 |
| US-20050186244-A1 | Polymer compositions and methods for their use | COL2A1, COL14A1, COL1A1 | TLR4 616/4885LY96 747/4885NR5A2 3542/4885 |
| US-20100227835-A1 | SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA | LIPG, FUT6, UGCG | TLR4 94/4885LY96 382/4885NR5A2 4679/4885 |
| US-20050169961-A1 | Implantable sensors and implantable pumps and anti-scarring agents | MMP1, CDKN1A, MKI67 | TLR4 2345/4885LY96 617/4885NR5A2 2005/4885 |
| US-20050175665-A1 | In combination with antiscarring, antifibrotic, and antiinflammatory agents for preventing surgical adhesions, and cartilage loss; hypertrophic scars, keloids, arthritis, vascular disease; injection or topical administration | MMP1, COL2A1, MMP13 | TLR4 1276/4885LY96 766/4885NR5A2 1697/4885 |
| US-20050154374-A1 | Implantable sensors and implantable pumps and anti-scarring agents | MMP1, CDKN1A, MKI67 | TLR4 2345/4885LY96 617/4885NR5A2 2005/4885 |
| US-20050175703-A1 | Polymer compositions and methods for their use | COL2A1, COL14A1, COL1A1 | TLR4 616/4885LY96 747/4885NR5A2 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.